Read our latest updates & insights

Onco’Zine reports a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz’s Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced febrile neut...

Medicure announces it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar product for EU, US and Canada. Medicure is responsible for the regulatory approval process for that product.

Lupin receives approval for biosimilar etanercept in Australia under the trade names Etera® and Rymti® in PFS presentations.

California’s Governor Gavin Newsom signed legislation to lower the cost of prescription drugs. The legislation, SB852, allows the California Health and Human Services Agency (CHHS) to develop manufacturing partnerships to produce or distribute generic prescription dru...

The University of Oxford announces it has commenced Ph II trials of adalimumab as a treatment for patients with COVID-19. The trial will enrol up to 750 patients from community care settings throughout the UK and is funded by the COVID-19 Therapeutics Accelerator, an initia...

Centus Biotherapeutics announces it has received EC marketing authorisation for Equidacent® (biosimilar bevacizumab). Equidacent® has been exclusively licensed to Fujifilm Kyowa Kirin Biologics on a worldwide basis.

The Alliance of Community Health Plans (ACHP) released a new report ‘Health Care 2030: ACHP’s Roadmap to Reform’ which calls for nonpartisan and practical changes to the American healthcare system. Among these proposed changes, ACHP has called for reforms ...

Significant biosimilar activities this week include
21 Sep 20 | EU | Alexion announced it has received a positive opinion from the EU’s CHMP for a new 100mg/mL formulation of Ultomiris® (ravulizumab).  The new formulation requires an infusion time of 0.4 hours t...

Innovent announces its ph III trial of Byvasda® (proposed bevacizumab biosimilar) in combination with Tyvyt® (sintilimab) met its primary endpoints of progression-free survival and overall survival. Innovent reported that the safety profile of both products was consistent w...